Brief: Xbiotech And Biobridge Global Collaborate On FDA Program To Develop Potential COVID-19 Treatment Based On Natural Antibodies From Recovered Patients
03/04/2020 21:55
April 3 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH AND BIOBRIDGE GLOBAL COLLABORATE ON FDA PROGRAM
TO
DEVELOP POTENTIAL COVID-19 TREATMENT BASED ON NATURAL ANTIBODIES
FROM RECOVERED PATIENTS
Source text for Eikon: ID:nGNX6Dh22K
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke